Typical therapeutic targets to control hyperglycemia in T2D patients are those enzymes involved in the regulation of post-prandial blood glucose levels such as α-amylase, α-glucosidase, and dipeptidyl peptidase-IV (DPP-IV) [6,7]. Here, DPP4 is linked to type 2 diabetes mellitus.